Vaccination of rainbow trout, Oncorhynchus mykiss (Walbaum), with recombinant and DNA vaccines produced to Flavobacterium psychrophilum heat shock proteins 60 and 70

Flavobacterium psychrophilum heat shock proteins (Hsp) 60 and 70 are highly immunogenic and were therefore investigated as potential vaccine candidates. Recombinant Hsps were purified from Escherichia coli and rainbow trout ( Oncorhynchus mykiss ) were intraperitoneally injected with phosphate buffered saline/Freunds complete adjuvant (FCA), 8 μg of rHsp60/FCA, rHsp70/FCA or a combination of 4 μg each of rHsp60 and rHsp70/FCA. Antibody responses against recombinant Hsp60 and Hsp70 8 weeks post-immunization were observed, but only fish immunized with rHsp70 exhibited highly elevated antibody levels against F. psychrophilum whole cell lysate. Some cross reactivity occurred, which may have been due to the V5 tag common to both proteins. Protection against F. psychrophilum challenge was not observed in any treatments at 8 weeks post-immunization. To further investigate any protective effect of these proteins, hsps were polymerase chain reaction amplified and cloned into pVAX1. Rainbow trout were intramuscularly injected with 8 μg of pVAX1hsp60, pVAX1hsp70 or a combination of 4 μg each of pVAX1hsp60 and pVAX1hsp70. Antibody responses at 4 weeks post-immunization were low and protection was not observed following challenge at 6 or 10 weeks post-immunization. Although Hsps of F. psychrophilum have been shown to be immunodominant, these antigens do not appear to be good vaccine candidates when delivered alone or in combination.     

草鱼多联佐剂疫苗的研制——Ⅰ. 疫苗的制备及免疫原性的研究

用草鱼出血病、肠炎病、赤皮病和烂鳃病的病原与PHA按一定比例混合制成联合疫苗,注射当年草鱼,安全性好,对上述各病的免疫保护率(%)依次为93.3±1.5,77.43±12.25,68.2±4.66和B6±2.55;免疫鱼血清抗体效价分别为1047.7±561.2,354.6±120.5,57.6±14.3和2379.2±37B.9;外周血ANAE阳性淋巴细胞的百分率(‰)为63.2±3.4.63.4±l.8,60.2±1.79和63±2.74,与来免疫鱼有极其显著的差异(P<0.01)。     

Efficacy of strain RB51 vaccine in protecting infection and vertical transmission against Brucella abortus in Sprague-Dawley rats

Immunizing animals in the wild against Brucella (B.) abortus is essential to control bovine brucellosis because cattle can get the disease through close contact with infected wildlife. The aim of this experiment was to evaluate the effectiveness of the B. abortus strain RB51 vaccine in protecting infection as well as vertical transmission in Sprague-Dawley (SD) rats against B. abortus biotype 1. Virgin female SD rats (n = 48) two months of age were divided into two groups: one group (n = 24) received RB51 vaccine intraperitoneally with 3 × 10¹⁰ colony forming units (CFU) and the other group (n = 24) was used as non-vaccinated control. Non-vaccinated and RB51-vaccinated rats were challenged with 1.5 × 10⁹ CFU of virulent B. abortus biotype 1 six weeks after vaccination. Three weeks after challenge, all rats were bred. Verification of RB51-vaccine induced protection in SD rats was determined by bacteriological, serological and molecular screening of maternal and fetal tissues at necropsy. The RB51 vaccine elicited 81.25% protection in SD rats against infection with B. abortus biotype 1. Offspring from rats vaccinated with RB51 had a decreased (p < 0.05) prevalence of vertical transmission of B. abortus biotype 1 compared to the offspring from non-vaccinated rats (20.23% and 87.50%, respectively). This is the first report of RB51 vaccination efficacy against the vertical transmission of B. abortus in the SD rat model.     

An experimental vaccine against Aeromonas hydrophila can induce protection in rainbow trout,Oncorhynchus mykiss (Walbaum)

A candidate vaccine against Aeromonas hydrophila in rainbow trout, Oncorhynchus mykiss, was developed using a bacterial lysate. To test the strength of protection, A. hydrophila challenge models were compared using injection into both the intraperitoneal (IP) cavity and the dorsal sinus (DS) with selected doses of live bacteria washed in saline or left untreated. Unlike the IP route, injection into the DS with either saline washed or unwashed cells resulted in consistent cumulative mortality and a dose response that could be used to establish a standard challenge having an LD₅₀ of approximately 3 × 10⁷ colony forming units per fish. Survivors of the challenge suffered significantly lower mortality upon re‐challenge than naïve fish, suggesting a high level of acquired resistance was elicited by infection. Passive immunization using serum from hyper‐immunized fish also resulted in significantly reduced mortality indicating protection can be transferred and that some portion of resistance may be antibody mediated. Vaccination of groups of rainbow trout with A. hydrophila lysate resulted in significant protection against a high challenge dose but only when injected along with Freund’s complete adjuvant. At a low challenge dose, mortality in all groups was low, but the bacterial lysate alone appeared to offer some protection.     

西藏兔病毒性出血症的研究--病原鉴定及疫苗免疫效力试验

１９９４年６￣７月,西藏林芝地区家兔大批急性死亡同,经过流行病学调查,临诊断症状观察,病理剖检等结果与兔病毒性出血症特征相符。进一步作病毒学检查表明,病变组织超薄发切片经电子显微镜观察发现有大量直径约３０ｎｍ的球状裸听病毒粒子,自然病死兔肝组织匀交涉 清能凝集入）型红细胞,而且血凝兔出血症病毒阳性抗血清所抑制,致病性试验结果表明,该病毒对兔有很强的致病性;用西藏自然病死兔肝组织匀浆试制的矩形疫苗兔     

猪链球菌病及其疫苗研究进展

猪链球菌病(Swine streptococosis)是由多种不同血清群的致病性链球菌引起的一种疾病总称.近年来猪链球菌病在我国已广泛流行,特别是C群兽疫链球菌(现称马链球茵兽疫亚种)病,严重影响着我国的养殖业,造成了很大的经济损失.文章主要从其病原学、流行病学、毒力因子、病理变化、疫苗的研究进展做了系统的阐述,为该病的深入研究提供参考.     

黏膜疫苗抗原运输方式及佐剂研究进展

黏膜免疫是机体防御感染的第一道防线,诱导有效的黏膜免疫应答对病原由黏膜感染途径引发的疾病预防具有重要的意义.目前,在黏膜疫苗的研究中存在某些关键性问题,最重要的是黏膜抗原不能有效地被运输至黏膜诱发部位,致使黏膜免疫系统不能被有效刺激,而不能产生高效的免疫应答.因此,选择安全而有效的黏膜佐剂及选择有效的抗原运输系统是发展黏膜疫苗的必须条件.论文就近几年来黏膜疫苗佐剂及抗原运输方式进行综述.     

New gene-based approaches for an AIDS vaccine

Vaccine approaches against AIDS have focused on inducing cellular immune responses, since many studies revealed the role of T cell responses in the control of human immunodeficiency virus or simian immunodeficiency virus (SIV) infections. The experimental infection of rhesus macaques with SIV or chimeric SHIV is routinely used as a model for AIDS. In such models, DNA immunization is a tool to elicit specific T cell responses and to study their protective efficacy. DNA immunogenicity in primates depends on parameters such as level of antigen expression, choice of the antigen among SIV proteins, use of fusion proteins, route of immunization, and addition of adjuvants. Recent results suggest that priming with DNA and boosting with attenuated recombinant viral vectors, each expressing corresponding SIV antigens, leads to improved specific immunity and, in some cases, affords protection against pathogenic challenge. After preclinical evaluations, DNA has entered clinical trials for a therapeutic or prophylactic gene-based AIDS vaccine.